» Articles » PMID: 34680250

Survival Is Related to Estrogen Signal Transduction Pathway Activity in Postmenopausal Women Diagnosed with High-Grade Serous Ovarian Carcinoma

Abstract

High-grade serous ovarian carcinoma (HGSC), the most common subtype of ovarian cancer, has a high mortality rate. Although there are some factors associated with survival, such as stage of disease, there are remarkable differences in survival among women diagnosed with advanced stage disease. In this study, we investigate possible relations between survival and signal transduction pathway (STP) activity. We assessed the functional activity of the androgen receptor (AR), estrogen receptor (ER), phosphoinositide-3-kinase (PI3K), Hedgehog (HH), transforming growth factor beta (TGF-β) and canonical wingless-type MMTV integration site (Wnt) pathway in 85 primary tumor samples of patients with FIGO stage IIIC to IVB HGSC and disease-free survival (DFS) below 12 ( = 52) or over 24 months ( = 33). There were no significant differences in median pathway activity between patients with a short and long DFS. In univariate Cox proportional hazards analysis, ER pathway activity was related to a favorable DFS and overall survival (OS) in postmenopausal women ( = 0.033 and = 0.041, respectively), but not in premenopausal women. We divided the postmenopausal group into subgroups based on ER pathway activity quartiles. Survival analysis revealed that postmenopausal women in the lowest ER quartile had a shorter DFS and OS (log-rank = 0.006 and < 0.001, respectively). Furthermore, we were able to form subgroups of patients based on an inverse relation between ER and PI3K pathway activity. In conclusion, in postmenopausal patients with advanced stage HGSC, a poorer survival outcome was associated with low functional ER pathway activity.

Citing Articles

Patient-Representative Cell Line Models in a Heterogeneous Disease: Comparison of Signaling Transduction Pathway Activity Between Ovarian Cancer Cell Lines and Ovarian Cancer.

Hendrikse C, Theelen P, Verhaegh W, Lambrechts S, Bekkers R, van de Stolpe A Cancers (Basel). 2024; 16(23).

PMID: 39682227 PMC: 11640608. DOI: 10.3390/cancers16234041.


Steroid metabolism and hormonal dynamics in normal and malignant ovaries.

Beevors L, Sundar S, Foster P Essays Biochem. 2024; 68(4):491-507.

PMID: 38994724 PMC: 11625866. DOI: 10.1042/EBC20240028.


Steroid sulfatase and sulfotransferases in the estrogen and androgen action of gynecological cancers: current status and perspectives.

Rizner T, Gjorgoska M Essays Biochem. 2024; 68(4):411-422.

PMID: 38994718 PMC: 11625860. DOI: 10.1042/EBC20230096.


Phenotype-guided targeted therapy based on functional signal transduction pathway activity in recurrent ovarian cancer patients: The STAPOVER study protocol.

van der Ploeg P, Hendrikse C, Thijs A, Westgeest H, Smedts H, Caroline Vos M Heliyon. 2024; 10(1):e23170.

PMID: 38187310 PMC: 10770441. DOI: 10.1016/j.heliyon.2023.e23170.

References
1.
Mal R, Magner A, David J, Datta J, Vallabhaneni M, Kassem M . Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor. Front Oncol. 2020; 10:587386. PMC: 7645238. DOI: 10.3389/fonc.2020.587386. View

2.
Sieh W, Kobel M, Longacre T, Bowtell D, DeFazio A, Goodman M . Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncol. 2013; 14(9):853-62. PMC: 4006367. DOI: 10.1016/S1470-2045(13)70253-5. View

3.
Shen Z, Luo H, Li S, Sheng B, Zhao M, Zhu H . Correlation between estrogen receptor expression and prognosis in epithelial ovarian cancer: a meta-analysis. Oncotarget. 2017; 8(37):62400-62413. PMC: 5617514. DOI: 10.18632/oncotarget.18253. View

4.
Liu H, Yin J, Wang H, Jiang G, Deng M, Zhang G . FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Cell Signal. 2015; 27(3):510-8. DOI: 10.1016/j.cellsig.2015.01.001. View

5.
Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View